As of 2025-03-20, the Relative Valuation of Protagonist Therapeutics Inc (PTGX) is 153.39 USD. This relative valuation is based on P/E multiples. With the latest stock price at 54.35 USD, the upside of Protagonist Therapeutics Inc based on Relative Valuation is 182.2%.
The range of the Relative Valuation is 94.14 - 217.98 USD.
| Range | Selected | |
| Trailing P/E multiples | 31.6x - 48.6x | 41.5x |
| Forward P/E multiples | 27.1x - 48.9x | 34.7x |
| Fair Price | 94.14 - 217.98 | 153.39 |
| Upside | 73.2% - 301.1% | 182.2% |
| Date | P/E |
| 2025-03-14 | 12.22 |
| 2025-03-13 | 12.25 |
| 2025-03-12 | 12.86 |
| 2025-03-11 | 13.33 |
| 2025-03-10 | 12.48 |
| 2025-03-07 | 8.55 |
| 2025-03-06 | 8.71 |
| 2025-03-05 | 8.58 |
| 2025-03-04 | 8.62 |
| 2025-03-03 | 8.59 |
| 2025-02-28 | 8.38 |
| 2025-02-27 | 8.11 |
| 2025-02-26 | 8.06 |
| 2025-02-25 | 7.83 |
| 2025-02-24 | 8.03 |
| 2025-02-21 | 8.64 |
| 2025-02-20 | 8.59 |
| 2025-02-19 | 8.59 |
| 2025-02-18 | 8.42 |
| 2025-02-14 | 8.63 |
| 2025-02-13 | 8.63 |
| 2025-02-12 | 8.35 |
| 2025-02-11 | 8.25 |
| 2025-02-10 | 8.47 |
| 2025-02-07 | 8.67 |
| 2025-02-06 | 8.42 |
| 2025-02-05 | 8.59 |
| 2025-02-04 | 8.38 |
| 2025-02-03 | 8.30 |
| 2025-01-31 | 8.43 |
| 2025-01-30 | 8.73 |
| 2025-01-29 | 8.52 |
| 2025-01-28 | 8.47 |
| 2025-01-27 | 8.56 |
| 2025-01-24 | 8.41 |
| 2025-01-23 | 8.43 |
| 2025-01-22 | 8.23 |
| 2025-01-21 | 8.50 |
| 2025-01-17 | 8.21 |
| 2025-01-16 | 8.15 |
| 2025-01-15 | 8.46 |
| 2025-01-14 | 8.18 |
| 2025-01-13 | 8.28 |
| 2025-01-10 | 8.17 |
| 2025-01-08 | 8.39 |
| 2025-01-07 | 8.58 |
| 2025-01-06 | 8.50 |
| 2025-01-03 | 8.83 |
| 2025-01-02 | 8.69 |
| 2024-12-31 | 8.61 |